Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Your age may not tell the whole story about your health, but your blood could (opens in a new tab)

news-medical.net · 2026-10-18

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of six claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 3 supported
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredThe study found that a panel of 56 age-related metabolites retained most of the age-predictive information from 232 metabolite features.View evidenceHide evidence

As stated56 age-related metabolites; 232 metabolite features

Why this verdict

The abstract-level profile supports identification of 56 representative age-associated metabolites. However, it does not mention 232 metabolite features or the claim that the 56-metabolite panel retained most age-predictive information from those features, so that more specific performance/feature-retention claim is not verifiable at abstract depth.

1

Study evidence

Plasma metabolomes were profiled in 18,476 participants aged 1–96 years across six centers in China using nano-assisted LDI-MS.

“we profiled plasma metabolomes from 18,476 participants aged 1 to 96 years across six centers in China using nano-assisted laser desorption/ionization mass spectrometry (LDI-MS) and identified 56 representative age-associated metabolites.”
2

Study evidence

A stacking ensemble model was developed in a healthy cohort to estimate metabolomic age from plasma metabolomic profiles.

“In a healthy cohort, we developed a stacking ensemble model to estimate metabolomic age and quantified metabolomic age acceleration (mAA) as each individual's deviation from chronological age.”
Claim 2 of 6Not coveredHigher metabolomic age acceleration was linked to smoking, secondhand smoke exposure, hair dye use, shift work, parental history of premature cardiovascular disease, and greater mortality risk after accounting for established health measures.View evidenceHide evidence

Why this verdict

The profile supports the broad statement that higher mAA was associated with unfavorable lifestyles, health deterioration, and increased all-cause mortality. It does not provide the named exposures—smoking, secondhand smoke exposure, hair dye use, shift work, or parental premature cardiovascular disease—nor the stated adjustment 'after accounting for established health measures.' Those specifics are not verifiable from the abstract-level profile.

1

Study evidence

A stacking ensemble model was developed in a healthy cohort to estimate metabolomic age from plasma metabolomic profiles.

“In a healthy cohort, we developed a stacking ensemble model to estimate metabolomic age and quantified metabolomic age acceleration (mAA) as each individual's deviation from chronological age.”
2

Study evidence

Individuals with accelerated metabolomic age acceleration (mAA) experienced increased risk of incident fatty liver disease during follow-up (2019–2025).

“During follow-up from 2019 to 2025, individuals with accelerated mAA showed increased risk of incident chronic diseases, such as fatty liver disease, hypertension, and diabetes, as well as increased all-cause mortality.”
Claim 3 of 6Not coveredThe article says the findings do not establish that individual foods or lifestyle changes directly affect biological aging, and that the metrics need mechanistic studies and independent validation before immediate clinical application.View evidenceHide evidence

Why this verdict

The observational/non-causal caution is consistent with the profile, especially for cross-sectional health/lifestyle associations. But the fuller claim that the article says individual foods or lifestyle changes do not directly affect biological aging, and that mechanistic studies plus independent validation are needed before clinical application, is not stated in the abstract-level profile. It may be true in the full paper or story, but it is not verifiable at this evidence depth.

1

Study evidence

Plasma metabolomes were profiled in 18,476 participants aged 1–96 years across six centers in China using nano-assisted LDI-MS.

“we profiled plasma metabolomes from 18,476 participants aged 1 to 96 years across six centers in China using nano-assisted laser desorption/ionization mass spectrometry (LDI-MS) and identified 56 representative age-associated metabolites.”
2

Study evidence

A stacking ensemble model was developed in a healthy cohort to estimate metabolomic age from plasma metabolomic profiles.

“In a healthy cohort, we developed a stacking ensemble model to estimate metabolomic age and quantified metabolomic age acceleration (mAA) as each individual's deviation from chronological age.”
Claim 4 of 6SupportedScientists examined metabolic patterns across 96 years of life to investigate their relationship with health and longevity.View evidenceHide evidence

As stated96 years of life

Why this verdict

The abstract-level profile supports that the study profiled plasma metabolomes across ages 1–96 and related derived metabolomic aging measures to health status, lifestyle factors, incident chronic disease, and mortality. This is supported if read as a cross-sectional age-span sample plus follow-up outcomes, not as within-person tracking across 96 years.

1

Study evidence

Plasma metabolomes were profiled in 18,476 participants aged 1–96 years across six centers in China using nano-assisted LDI-MS.

“we profiled plasma metabolomes from 18,476 participants aged 1 to 96 years across six centers in China using nano-assisted laser desorption/ionization mass spectrometry (LDI-MS) and identified 56 representative age-associated metabolites.”
2

Study evidence

A stacking ensemble model was developed in a healthy cohort to estimate metabolomic age from plasma metabolomic profiles.

“In a healthy cohort, we developed a stacking ensemble model to estimate metabolomic age and quantified metabolomic age acceleration (mAA) as each individual's deviation from chronological age.”
Claim 5 of 6SupportedIn a recent study published in Science Translational Medicine, researchers developed two metabolomic aging metrics using metabolic data from over 18,000 individuals aged 1 to 96 years.View evidenceHide evidence

As statedover 18,000 individuals aged 1 to 96 years

Why this verdict

The profile reports 18,476 participants aged 1–96 years, development of a metabolomic age/mAA clock in a healthy cohort, and a separate mortality-linked metabolomic metric in a disease cohort. The journal venue is not independently evidenced in the supplied profile, but the central scientific content of the claim is supported.

1

Study evidence

Plasma metabolomes were profiled in 18,476 participants aged 1–96 years across six centers in China using nano-assisted LDI-MS.

“we profiled plasma metabolomes from 18,476 participants aged 1 to 96 years across six centers in China using nano-assisted laser desorption/ionization mass spectrometry (LDI-MS) and identified 56 representative age-associated metabolites.”
2

Study evidence

A stacking ensemble model was developed in a healthy cohort to estimate metabolomic age from plasma metabolomic profiles.

“In a healthy cohort, we developed a stacking ensemble model to estimate metabolomic age and quantified metabolomic age acceleration (mAA) as each individual's deviation from chronological age.”
Claim 6 of 6SupportedParticipants with accelerated metabolomic aging were more likely to develop chronic conditions such as diabetes, hypertension, and fatty liver disease, and had a higher risk of death from any cause.View evidenceHide evidence

Why this verdict

The abstract-level profile directly reports that individuals with accelerated mAA had increased risk of incident fatty liver disease, hypertension, diabetes, and all-cause mortality during follow-up from 2019 to 2025. The claim is framed associationally and does not assert causality.

1

Study evidence

Individuals with accelerated metabolomic age acceleration (mAA) experienced increased risk of incident fatty liver disease during follow-up (2019–2025).

“During follow-up from 2019 to 2025, individuals with accelerated mAA showed increased risk of incident chronic diseases, such as fatty liver disease, hypertension, and diabetes, as well as increased all-cause mortality.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Separate disease-cohort mortality-linked metabolomic metric, 'age deviation,' associated with composite health measures, multisystem disease involvement, and multimorbidity burden.

    The story broadly says two metabolomic aging metrics were developed, but it does not clearly describe the separate disease cohort, the age-deviation construct, or its associations with multimorbidity and multisystem disease involvement.

    From Observational disease cohort; predictive/metabolomic modeling to derive mortality-linked metric

7 things the story did carry across
  • Large multi-center plasma metabolomics dataset: 18,476 participants aged 1–96 years across six centers in China, measured by nano-assisted LDI-MS.
  • Identification of 56 representative age-associated plasma metabolites defining metabolomic signatures of aging.
  • Development of a stacking-ensemble metabolomic age model and definition of metabolomic age acceleration as deviation from chronological age.
  • Cross-sectional associations between higher mAA and contemporaneous health deterioration and unfavorable lifestyle factors.
  • Longitudinal follow-up from 2019 to 2025 associating accelerated mAA with incident fatty liver disease, hypertension, diabetes, and all-cause mortality.
  • Key limitation: cross-sectional metabolomic profiling and cross-sectional mAA-health/lifestyle associations do not establish within-person aging trajectories, temporality, or causality.
  • Key limitation: the studied population was from six centers in China, limiting direct generalization to other populations without validation.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDevelop and validate a metabolomic aging clock (metabolomic age) using ensemble learning in a healthy cohort, and relate metabolomic age acceleration (mAA) to contemporaneous health and lifestyle factors.stacking ensemble metabolomic age model development (healthy cohort)Expand

In plain English

The authors profiled plasma metabolomes from 18,476 participants (age 1–96) using LDI-MS and, within a healthy cohort, trained a stacking ensemble to predict chronological age (metabolomic age). They defined metabolomic age acceleration (mAA) as the individual's deviation from chronological age and tested cross-sectional associations between mAA and contemporaneous health deterioration and unfavorable lifestyle factors.

Key findings

  • A stacking ensemble model was developed in a healthy cohort to estimate metabolomic age from plasma metabolomic profiles.
  • Metabolomic age acceleration (mAA) was defined as each individual's deviation from chronological age (prediction residual).
“In a healthy cohort, we developed a stacking ensemble model to estimate metabolomic age and quantified metabolomic age acceleration (mAA) as each individual's deviation from chronological age.”
What this piece can’t prove

4 further details could not be confirmed from the summary.

2human in vivoDefine plasma metabolomic signatures of aging across the human life span and identify representative age-associated metabolites from a large multi-center cohort.Cross-sectional multi-center plasma metabolomics profilingExpand

In plain English

Multi-center cross-sectional plasma metabolomics profiling (nano-assisted LDI-MS) of 18,476 participants aged 1–96 years across six centers in China identified 56 representative age-associated plasma metabolites, defining metabolomic signatures of aging across the human life span.

Key findings

  • Plasma metabolomes were profiled in 18,476 participants aged 1–96 years across six centers in China using nano-assisted LDI-MS.
  • Analysis identified a set of 56 representative age-associated plasma metabolites that characterize metabolomic signatures across the life span.
“we profiled plasma metabolomes from 18,476 participants aged 1 to 96 years across six centers in China using nano-assisted laser desorption/ionization mass spectrometry (LDI-MS) and identified 56 representative age-associated metabolites.”
What this piece can’t prove
  • Cross-sectional profiling limits inference about within-individual longitudinal changes in metabolite levels with aging.
  • Abstract does not report analytic details (e.g., normalization, covariates, statistical tests, multiple testing correction, or criteria for selecting the 56 representative metabolites).

1 further detail could not be confirmed from the summary.

3human in vivoTest whether metabolomic age acceleration (mAA) predicts future incident chronic diseases and all-cause mortality during longitudinal follow-up.Prospective cohort follow-upExpand

In plain English

In a prospective longitudinal analysis over 2019–2025, the authors report that individuals with accelerated metabolomic age acceleration (mAA)—defined as the deviation of metabolomic-estimated age from chronological age—had increased risk of incident chronic diseases (fatty liver disease, hypertension, diabetes) and increased all-cause mortality. The exposure (mAA) was derived from a stacking ensemble metabolomic age model trained on plasma LDI‑MS profiles. The abstract does not report effect estimates, sample sizes for the longitudinal analysis, or adjustment/covariate details.

Key findings

  • Individuals with accelerated metabolomic age acceleration (mAA) experienced increased risk of incident fatty liver disease during follow-up (2019–2025).
  • Individuals with accelerated mAA experienced increased risk of incident hypertension during follow-up (2019–2025).
“During follow-up from 2019 to 2025, individuals with accelerated mAA showed increased risk of incident chronic diseases, such as fatty liver disease, hypertension, and diabetes, as well as increased all-cause mortality.”
What this piece can’t prove
  • Abstract does not report effect sizes, measures of precision (CIs), p-values, or model covariates for the longitudinal associations.

3 further details could not be confirmed from the summary.

4human in vivoIn a disease cohort, develop a mortality-linked metabolomic metric (age deviation) reflecting departures from age-expected mortality risk and associate it with composite health measures and multimorbidity burden.Observational disease cohort; predictive/metabolomic modeling to derive mortality-linked metricExpand

In plain English

In a separate disease cohort, the authors derived a mortality-linked metabolomic metric called “age deviation” from plasma metabolite profiles (LDI-MS). Age deviation quantified individualized departures from age-expected mortality risk inferred from metabolites and was associated with established composite health measures and increased with multisystem disease involvement and higher multimorbidity burden.

Key findings

  • A mortality-linked metabolomic metric (“age deviation”) was derived from plasma metabolites in a disease cohort and quantified individualized departures from age-expected mortality risk.
  • Age deviation was associated with established composite health measures and increased with multisystem disease involvement and higher multimorbidity burden.
“In a disease cohort, we further developed a mortality-linked metabolomic metric (age deviation) that quantified individualized departures from age-expected mortality risk inferred from plasma metabolites.”
What this piece can’t prove
  • The abstract does not provide quantitative effect estimates, statistical tests, or model performance metrics for the mortality-linked metric or its associations.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 32 candidate papers

And 26 more candidates considered.